Business Description
Medeon Biodesign Inc
ISIN : TW0006499007
Description
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.53 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 5.84 | |||||
| Beneish M-Score | -1.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -13.2 | |||||
| 3-Year EBITDA Growth Rate | -28.9 | |||||
| 3-Year EPS without NRI Growth Rate | -18.2 | |||||
| 3-Year FCF Growth Rate | -26.9 | |||||
| 3-Year Book Growth Rate | 21.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.64 | |||||
| 9-Day RSI | 48.29 | |||||
| 14-Day RSI | 47.33 | |||||
| 6-1 Month Momentum % | -8.22 | |||||
| 12-1 Month Momentum % | -20.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.93 | |||||
| Quick Ratio | 11.9 | |||||
| Cash Ratio | 11.51 | |||||
| Days Inventory | 18.5 | |||||
| Days Sales Outstanding | 79.56 | |||||
| Days Payable | 12.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.18 | |||||
| Forward Dividend Yield % | 1.18 | |||||
| 5-Year Yield-on-Cost % | 1.18 | |||||
| 3-Year Average Share Buyback Ratio | 0.1 | |||||
| Shareholder Yield % | -1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 10.14 | |||||
| Operating Margin % | -456.05 | |||||
| Net Margin % | -666.63 | |||||
| FCF Margin % | -441.28 | |||||
| ROE % | -36.97 | |||||
| ROA % | -32.28 | |||||
| ROIC % | -49.02 | |||||
| ROC (Joel Greenblatt) % | -347.01 | |||||
| ROCE % | -34.9 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 22.67 | |||||
| PB Ratio | 1.55 | |||||
| Price-to-Tangible-Book | 1.66 | |||||
| EV-to-EBIT | -1.46 | |||||
| EV-to-EBITDA | -1.58 | |||||
| EV-to-Revenue | 9.92 | |||||
| EV-to-FCF | -2.21 | |||||
| Price-to-Net-Current-Asset-Value | 1.96 | |||||
| Price-to-Net-Cash | 2.05 | |||||
| Earnings Yield (Greenblatt) % | -68.17 | |||||
| FCF Yield % | -20.02 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers